Massachussetts Biotech Co. Faces Major Melanoma Drug Setback
Source: Streetwise Reports  (4/14/26)
Replimune Group Inc.'s (REPL:NASDAQ) RP1 melanoma therapy hits FDA rejection, raising uncertainty around approval timelines and future market potential. More >

Biotech Firm Advances Voice-Based Intoxication Tech Aiming to Revolutionize Medical Diagnostics
Source: Streetwise Reports  (4/13/26)
MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) AI voice model analyzes 140+ biomarkers, targeting non-invasive impairment screening. More >

MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA
Source: Robert Burns  (4/13/26)
H.C. Wainwright downgraded Replimune Group (REPL:NASDAQ) to Sell after the FDA issued a second Complete Response Letter for the RP-1 plus Opdivo BLA in anti-PD1 failed melanoma. More >

What Do Analysts Think About the Biopharma Set on Transforming Psychiatry
Source: Streetwise Reports  (4/9/26)
Alto Neuroscience Inc. (ANRO:NYSE) is a clinical-stage biopharmaceutical company focused on transforming psychiatry through novel drug candidates. More >

Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion
Source: Streetwise Reports  (4/8/26)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) appoints Chilean policy leader Felipe Leyton for the mining rollout of its AI impairment detection tech. More >

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial
Source: Dr. Ananda Ghosh  (4/7/26)
H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials. More >

California Biotech Co. Advances Depression Drug Breakthrough
Source: Streetwise Reports  (4/7/26)
Alto Neuroscience Inc. (ANRO:NYSE) pivots after mixed trial results, targeting treatment-resistant depression with analyst support and major market growth potential. More >

Name Change, Share Consolidation, and US Clinic Strategy Signal Shift Toward Alzheimer's Diagnostics
Source: Streetwise Reports  (4/6/26)
Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) plans to rebrand to Grey Matters Health Inc. while advancing its Alzheimer's diagnostic strategy and U.S. clinic rollout. More >

Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough
Source: Streetwise Reports  (4/2/26)
Cabaletta Bio Inc. (CABA:NASDAQ) pushes rese-cel CAR T program forward with strong clinical momentum, production scalability, and analyst-backed upside potential. More >

The World's First AI Voice Detection For Drugs & Alcohol With Charts That Beckon Investors To Buy
Source: Stewart Thomson  (4/1/26)
Technical Analyst Stewart Thomson explains why he thinks MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) is a Speculative Buy. More >

Biotech Company Uncovers Breakthrough Canine Arthritis Treatment
Source: Streetwise Reports  (3/30/26)
Israeli co. Can-Fite BioPharma Ltd. (CANF:NYSEAmerican) teamed up with Vetbiolix to trial Piclidenoson for dogs, with Phase 2 results due Q3 2026. Yet, one analyst still rates the stock as a Hold. Read on to see why. More >

First US Brain-Only PET Clinic Targets Alzheimer's Detection as Diagnostic Demand Expands
Source: Streetwise Reports  (3/27/26)
Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is opening its inaugural brain PET clinic in Florida with a five-year lease and renewal option. More >

Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough
Source: Streetwise Reports  (3/27/26)
Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) early results reveal dose-dependent drug exposure and significant biomarker reductions for forms of muscular dystrophy. More >

Biotech Company Achieves Key Bladder Cancer Milestone in California
Source: Streetwise Reports  (3/27/26)
ImmunityBio Inc. (IBRX:NASDAQ) confirms study power sufficiency for ANKTIVA combo, supporting measurable response outcomes and maintaining timeline for 2026 BLA filing. More >

Biotech Price Target Raised on Strong FSHD and DM1 siRNA Data
Source: Dr. Yun Zhong  (3/27/26)
Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising Phase 1/2 data for siRNA candidates SRP-1001 in FSHD and SRP-1003 in DM1, citing superior muscle concentration and a clean safety profile versus rival programs from Novartis and Dyne Therapeutics. More >

America's First Brain-Dedicated PET Scanning Clinics: A Turnaround Play for Chart-Savvy Investors?
Source: Stewart Thomson  (3/26/26)
Technical Analyst Stewart Thomson explains why he thinks Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is a Strong Speculative Buy. More >

Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline
Source: Mitchell Kapoor  (3/26/26)
H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics Inc. (SRPT:NASDAQ), arguing that promising but early-stage siRNA muscle concentration data in DM1 and FSHD cannot compensate for falling ELEVIDYS sales, a fatal adverse event in SRP-1003, and intensifying competition from Avidity and Dyne ahead of a potential 2030 market entry. More >

Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts and US$120M Financing
Source: Patrick Trucchio  (3/25/26)
H.C. Wainwright reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE), citing upcoming Phase 2 data readouts for ALTO-101, ALTO-300, and ALTO-100, plus US$120 million financing to advance ALTO-207 in treatment-resistant depression through Phase 3. More >

Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track
Source: Paul Matteis  (3/25/26)
Stifel reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE) after an in-line Q4 2025 earnings report. More >

Biotech Company Accelerates AI Detection Breakthrough Globally
Source: Streetwise Reports  (3/20/26)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) advanced AI-powered screening kiosks, targeting safer operations across industrial sectors. More >

Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity
Source: Streetwise Reports  (3/20/26)
Pelthos Therapeutics Inc. (PTHS:NYSEAmerican) delivered massive growth from its drug launch, with bullish forecasts signaling upside, according to analysts. More >

Life Sciences Firm Advances Massive US$2.4B Market Opportunity
Source: Streetwise Reports  (3/18/26)
Cleantech and life sciences leader BioLargo Inc. (BLGO:OTCQX) announces that clinical experiences with ViaCLYR were presented at a symposium in Hawaii. More >

An AI-Powered Doctor & Patient Platform: Why This North American Provider is Gaining Market Momentum
Source: Stewart Thomson  (3/17/26)
Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA). More >

Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch
Source: Andrew Fein  (3/16/26)
H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market. More >

Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands
Source: Dr. Yi Chen  (3/13/26)
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note. More >